11/20/2024
Emerging RSV Threat Highlights Need for Increased Vaccination Among Older Adults
Respiratory Syncytial Virus (RSV) poses a significant health risk to older adults. Despite the availability of Pfizer, GSK, and Moderna's three FDA-approved vaccines with over 80% efficacy, vaccination rates remain low. Enhanced public awareness, updated ACIP guidelines, and advanced vaccine research aim to increase its uptake.